Xenetic Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $4.43M
- P/E (TTM)
- –
- Dividend yield
- –
About Xenetic Biosciences
Pharmaceutical Preparations, SIC 2834
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing immuno-oncology technologies to address difficult-to-treat cancers. Its primary focus is a proprietary deoxyribonuclease (DNase) technology designed to target neutrophil extracellular traps, which are implicated in cancer growth, metastasis, and resistance to standard therapies like chemotherapy and immunotherapy. The company is advancing systemic DNase candidates into clinical development as adjunctive therapies for solid tumors, specifically targeting pancreatic ductal adenocarcinoma and colorectal carcinoma, alongside pre-clinical research into armored CAR T-cell therapies. It also licenses PolyXen, a proprietary drug delivery platform utilizing polysialic acid to improve protein and peptide stability.
The company maintains its principal executive offices in Framingham, Massachusetts. Its operations and development efforts involve collaborative relationships and research programs across the United States and Europe, including partnerships with academic and research entities such as The Scripps Research Institute, Catalent Pharma Solutions, and the University of Virginia.
Summary of the business section of Xenetic Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xenetic Biosciences, Inc.
- Founded
- 2014
- Headquarters
- Framingham, MA
- Address
- 945 Concord St. 01701
- Phone
- (781) 778-7720
- Website
- www.xeneticbio.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Hartford, CT
Stock & identifiers
- Ticker
- XBIO
- Exchange
- Nasdaq
- Shares outstanding
- 2M, Jul 31, 2026
- Public float
- $5.11M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Aug 10, 2023; 1-for-10 reverse, May 15, 2023; 1-for-12 reverse, Jun 25, 2019; 1-for-12 reverse, Jun 25, 2019; 1-for-33 reverse, Aug 15, 2016; 10-for-1, Apr 22, 2013
- SEC CIK
- 1534525
- CUSIP
- 984015602
- ISIN
- US9840156023
- LEI
- 5493002WV0KYX8JXAH52
- EIN
- 45-2952962
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James F. Parslow | Interim CEO and CFO | 100,000 |
| Roger D. Kornberg | Director | 0 |
| Firdaus J. Dastoor | Director | – |
| Grigory G. Borisenko | Director | – |
| Alexey Andreevich Vinogradov | Director | 186,781 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 James Parslow | $481.17K | $469.66K | $554.08K | $31 | – |
| FY2024 Jeffrey Eisenberg | $673.14K | $622.64K | $554.08K | $31 | – |
| FY2023 Jeffrey Eisenberg | $563.49K | $560.39K | $434.77K | $17 | – |
| FY2022 Jeffrey Eisenberg | $632.83K | $425.62K | $472.18K | $14 | – |
| FY2021 Jeffrey Eisenberg | $750.23K | $505.36K | $514.56K | $63 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2025, we employed two full-time employees.”
Corporate history
Events identified from SEC filings